{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:23:53Z","timestamp":1793618633227,"version":"4.5.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.1001\/jamacardio.2021.5083","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T08:30:36Z","timestamp":1636792236000},"page":"250","source":"Crossref","is-referenced-by-count":255,"title":["Association of Apolipoprotein B\u2013Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis"],"prefix":"10.1001","volume":"7","author":[{"given":"Nicholas A.","family":"Marston","sequence":"first","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio E. M.","family":"Melloni","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Morrill","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Initiative, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Blazing","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ference","sequence":"additional","affiliation":[{"name":"University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Stein","sequence":"additional","affiliation":[{"name":"Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Stroes","sequence":"additional","affiliation":[{"name":"University Medical Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Ellinor","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Initiative, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts"},{"name":"Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Demoulas Center for Cardiac Arrythmias, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Lubitz","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Initiative, The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts"},{"name":"Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston"},{"name":"Demoulas Center for Cardiac Arrythmias, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hoi210083r1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","article-title":"Factors of risk in the development of coronary heart disease\u2014six year follow-up experience. the Framingham Study.","volume":"55","author":"Kannel","year":"1961","journal-title":"Ann Intern Med"},{"issue":"23","key":"hoi210083r2","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease.","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hoi210083r3","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins.","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi210083r4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease.","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"hoi210083r5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable mendelian randomisation analysis.","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"issue":"7726","key":"hoi210083r6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"3","key":"hoi210083r7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"hoi210083r8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial.","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"issue":"18","key":"hoi210083r9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi210083r10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"issue":"25","key":"hoi210083r11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi210083r12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ije\/dym276","article-title":"The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine.","volume":"37","author":"Elliott","year":"2008","journal-title":"Int J Epidemiol"},{"issue":"4","key":"hoi210083r13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1373\/clinchem.2016.264515","article-title":"Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women.","volume":"63","author":"Lawler","year":"2017","journal-title":"Clin Chem"},{"issue":"11","key":"hoi210083r14","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL Cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients.","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi210083r15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review.","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"1","key":"hoi210083r16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi210083r17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.113.005873","article-title":"Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.","volume":"129","author":"Mora","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"hoi210083r18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"hoi210083r19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"hoi210083r20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2021.09.046","article-title":"Lipid measurement in the management of cardiovascular diseases: practical recommendations. a scientific statement from the National Lipid Associations Writing Group.","author":"Wilson","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"5","key":"hoi210083r21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1373\/clinchem.2012.196733","article-title":"Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices.","volume":"59","author":"Cole","year":"2013","journal-title":"Clin Chem"},{"issue":"7","key":"hoi210083r22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2786333\/jamacardiology_marston_2021_oi_210083_1646769466.17229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:16:46Z","timestamp":1646824606000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2786333"}},"subtitle":["Distinguishing Between Particle Concentration, Type, and Content"],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.5083","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}